Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of Serono Symposia International Foundation. All presentations solely represent the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

José Carlos Álvarez-Cermeño Declared receipt of grants and contracts from Merck-Serono, Bayer-Schering, Biogen Idec and to receive honoraria or consultation fees from Merck-Serono, Bayer-Schering, Biogen Idec, Teva, Sanofi Aventis. Declared also to be a member of the following companies advisory board, board of directors or other similar groups: Merck-Serono, Bayer-Schering, Biogen Idec.

Raul Arcega Declared no potential conflict of interest.

Bonaventura Casanova Declared to be a member of the following companies advisory board, board of directors or other similar groups: Merck-Serono, TEVA, Sanofi Aventis.

Francisco Coret Ferrer Declared to be member of TEVA advisory board, board of directors or other similar groups.

Jorge Correale Declared receipt of grants and contracts from Novartis Clinical Trials and to receive honoraria or consultation fees from Merck-Serono and Biogen Idec, Teva, Sanofi Aventis. Declared also to be a member of the following companies advisory board, board of directors or other similar groups: Merck-Serono, Biogen Idec.

Edgardo Cristiano Declared no potential conflict of interest.

Carlos Cuevas Garcia Declared receipt of grants and contracts from Teva, Merck Serono and Biogen and to receive honoraria or consultation fees from Teva and Biogen Idec. Declared also to be a member of Teva advisory board, board of directors or other similar groups.

Oscár Fernández Declared no potential conflict of interest.

Juan Antonio García Merino Declared receipt of honoraria or consultation fees from Merck-Serono, Biogen Idec and Novartis.

Rafael Lander Declared receipt of honoraria or consultation fees from Advisory Board Meetings.

Oliver Neuhaus Declared no potential conflict of interest.

Regina Papais-Alvarenga Declared receipt of grants and contracts from Merck-Serono, Teva, Novartis and Biogen Idec and to receive honoraria or consultation fees from Bayer-Schering. Declared also to be a member of Biogen Idec advisory board, board of directors or other similar groups.

Arnoldo Soto Declared receipt of honoraria or consultation fees from Abbott, Bayer and Merck Serono.

Antonio Uccelli Declared receipt of grants and contracts from Sanofi Aventis and to receive honoraria or consultation fees from Genetech, Roche, Allergan and Merck-Serono. Declared also to be a member of the following companies advisory board, board of directors or other similar groups: Roche and Allergan.

The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of April 30, 2010.

Txomin Arbizu
Giancarlo Comi
Marco Lana-Peixoto
Miguel Angel Macías
Heinz Wiendl